Literature DB >> 10632347

Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.

J Upadhyay1, B Shekarriz, J A Nemeth, Z Dong, G D Cummings, R Fridman, W Sakr, D J Grignon, M L Cher.   

Abstract

Membrane type 1-matrix metalloproteinase (MT1-MMP) is a known activator of latent MMP-2 (pro-MMP-2), and increased MMP-2 expression has been associated with tumor aggressiveness in prostate cancer. However, expression of MT1-MMP in human prostate tissue has not been described. We investigated the expression and immunolocalization of MT1-MMP and MMP-2 in the epithelial components of benign prostate epithelium, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostate cancer. Tissue sections from the peripheral zone of 50 prostates (radical prostatectomy specimens) were chosen based on their containing benign glands, HGPIN, and prostate cancer glands. All 50 sections were immunostained for MT1-MMP and MMP-2 and were evaluated for staining pattern, uniformity, and intensity. Western blotting and gelatin zymography were done to confirm expression of MT1-MMP and activity of MMP-2, respectively. Comparisons were made between benign epithelium, HGPIN, and cancer. In benign glands, basal cells (BCs) uniformly stained intensely for MT1-MMP, whereas secretory cells (SCs) were rarely positive (P < 0.0001). Conversely in HGPIN, SCs showed consistent cytoplasmic staining (P < 0.0001). In cancer cells, staining was heterogeneous and varied from no staining to very intense staining in select glands. MMP-2 in normal tissue stained both BCs and the apical region of SCs, whereas in HGPIN, staining was observed in the SC in a predominantly cytoplasmic pattern. Similar to MT1-MMP, staining in cancer tissue for MMP-2 was heterogeneous; however, there was a significant association between the pattern of MMP-2 and MT1-MMP staining within the epithelial components of the cancer glands in individual specimens (P < 0.001). Finally, MMP-2 and MT1-MMP were confirmed to be expressed in the prostate tissues by gelatin zymography and Western blotting. In conclusion, we found that consistent changes in localization and intracellular distribution of MMP-2 and MT1-MMP were associated with the transition from benign prostate epithelium to HGPIN, suggesting that regulation of these enzymes is altered during the earliest stages of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632347

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe.

Authors:  Walter J Akers; Baogang Xu; Hyeran Lee; Gail P Sudlow; Gregg B Fields; Samuel Achilefu; W Barry Edwards
Journal:  Bioconjug Chem       Date:  2012-02-29       Impact factor: 4.774

2.  Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.

Authors:  Zhong Dong; R Daniel Bonfil; Sreenivasa Chinni; Xiyun Deng; J Carlos Trindade Filho; Margarida Bernardo; Ulka Vaishampayan; Mingxin Che; Bonnie F Sloane; Shijie Sheng; Rafael Fridman; Michael L Cher
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

3.  Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide.

Authors:  Wei Wang; Ruping Shao; Qingping Wu; Shi Ke; John McMurray; Frederick F Lang; Chusilp Charnsangavej; Juri G Gelovani; Chun Li
Journal:  Mol Imaging Biol       Date:  2009-05-08       Impact factor: 3.488

4.  Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.

Authors:  Seaho Kim; Wei Huang; Emilio P Mottillo; Anjum Sohail; Yoon-Ah Ham; M Katie Conley-Lacomb; Chong Jai Kim; Guri Tzivion; Hyeong-Reh Choi Kim; Shihua Wang; Yong Q Chen; Rafael Fridman
Journal:  Biochim Biophys Acta       Date:  2010-07-08

5.  The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.

Authors:  Angèle Nalbandian; Daniel Djakiew
Journal:  Clin Exp Metastasis       Date:  2006-08-16       Impact factor: 5.150

6.  Membrane fluidity, invasiveness and dynamic phenotype of metastatic prostate cancer cells after treatment with soy isoflavones.

Authors:  Vladimir Ajdžanović; Marija Mojić; Danijela Maksimović-Ivanić; Mirna Bulatović; Sanja Mijatović; Verica Milošević; Ivan Spasojević
Journal:  J Membr Biol       Date:  2013-02-16       Impact factor: 1.843

7.  Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo.

Authors:  Xuan Zhang; Jamee Bresee; Gregg B Fields; W Barry Edwards
Journal:  Bioorg Med Chem Lett       Date:  2014-07-05       Impact factor: 2.823

8.  Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients.

Authors:  Christian G Sauer; Alexandra Kappeler; Monika Späth; Jens J Kaden; Maurice S Michel; Doris Mayer; Uwe Bleyl; Rainer Grobholz
Journal:  Virchows Arch       Date:  2004-04-16       Impact factor: 4.064

Review 9.  Bone metabolism and new targets for intervention.

Authors:  Bulent Akduman; E David Crawford
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

10.  The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.

Authors:  Chuanbo Zhang; Bhaskar V Kallakury; Jeffrey S Ross; Rajshree R Mewani; Christine E Sheehan; Isamu Sakabe; George Luta; Deepak Kumar; Sivaramakrishna Yadavalli; Joshua Starr; Taduru L Sreenath; Shiv Srivastava; Harvey B Pollard; Ofer Eidelman; Meera Srivastava; Usha N Kasid
Journal:  Int J Cancer       Date:  2013-01-10       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.